Common Incubation Centre at IIT Tirupati to boost food processing
District collector Dr S Venkateswar, Srikalahasti MLA Bojjala Sudhir Reddy, IIT Tirupati director Prof K N Satyanarayana, MoFPI joint secretary Devesh Dayal, state government's food processing secretary Chiranjeevi Chowdary and several others participated in the event.
The CIC is aimed at promoting entrepreneurship in the Chittoor and Tirupati regions, with a special focus on the food processing sector. The facility is designed to facilitate value addition and processing of locally abundant produce like tomatoes, mangoes (including mango pulp), and other agricultural commodities.
Appreciating IIT Tirupati's efforts in setting up the centre in collaboration with the MoFPI, Paswan said the Centre is committed to encouraging value addition and entrepreneurship in the food processing sector. He also assured that the government would extend all possible support for the successful completion of the project.
The minister appreciated the detailed proposal presented by IIT Tirupati director and the state government's food processing secretary and lauded the initiative's potential to strengthen the local economy.
Speaking at the event, MLA Sudhir Reddy praised IIT Tirupati for taking proactive steps to engage with local industries and youth. He said the incubation centre would be a game changer for the youth and farming communities of the region.
The MLA also suggested forming an advisory committee with government representatives to study the horticulture and food processing needs of Chittoor and Tirupati districts, and to encourage growth in these sectors.
District collector Venkateswar stated that Andhra Pradesh has made significant progress in the horticulture sector over the past 15 years, contributing around 9.5 per cent to the state's GDP. He mentioned that Tirupati district alone generates 9.25 per cent of its GDP from horticulture.
He noted that Rayalaseema, once known as a drought-prone region, has undergone a remarkable transformation through horticulture. Along with micro-irrigation methods like drip and sprinkler systems, around 5 to 6 lakh farm ponds have been created with the support of NREGS and as per the Chief Minister's directives. These efforts have improved groundwater levels, greatly benefiting the horticulture sector, he added.
IIT Tirupati director Prof Satyanarayana explained that the centre was conceived to foster rural entrepreneurs and startups in food processing, especially in Chittoor and Tirupati districts, which are major producers of tomatoes, mangoes, and other fruits.
The facility was established at a cost of Rs 3.95 crore, of which Rs 2.75 crore was provided by the ministry of food processing industries, while IIT Tirupati contributed Rs 1.2 crore from its own resources. To fully equip the centre, an additional Rs 60 lakh is still required.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
42 minutes ago
- Time of India
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.
Indian Express
an hour ago
- Indian Express
Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site
With two new campuses under construction in Northwest Delhi's Dheerpur and Rohini, Ambedkar University Delhi (AUD) is set to relocate from its heritage campus in Kashmere Gate. While the Dheerpur campus, spanning 4.95 acres, is being developed at a cost of Rs 1,199.02 crore, the Rohini campus, spread across 20 acres, will be set up for a cost of Rs 1,107.56 crore, The Indian Express has learnt. Both projects received statutory clearances in 2022, and the construction is underway. Vice-Chancellor Anu Singh Lather said the move was necessitated by infrastructural limitations and long-term maintenance costs at the existing site. 'The university building that we are functioning out of is a very old heritage building. We have maintained it well, but we will have to move out of here soon,' said Lather. 'It will take at least a couple of years for the construction of the new campuses to end and for us to relocate.' The current campus at Lothian Road in Kashmere Gate sits on a 3-acre site housing a 400-year-old building complex. According to the university's website, it has 'well-stocked libraries, reading rooms, online journals and computer labs,' as well as 'classrooms equipped with audio-visual equipment and WiFi connectivity'. Hostel facilities are available only for women. In addition to Kashmere Gate, AUD has been operating a 6.5-acre campus in Karampura on Shivaji Marg since 2016-17. Originally housing Deen Dayal Upadhyaya College and before that Shivaji College, the Karampura campus has been retrofitted with modern infrastructure. 'The Karampura campus has all the facilities that the Kashmere Gate campus have — technology-enabled AC classrooms, library, computer labs, student activity areas, playgrounds and cafeteria,' the university website states. Currently, over 800 students study at Karampura campus, which is also home to the School of Global Affairs (since 2018), and is expected to house the School of Vocational Studies and the School of Law and Governance in the coming years. A training kitchen and restaurant have also been set up for students of tourism and hospitality programmes. Established in 2008 by the Delhi government, AUD focuses on the humanities and social sciences and is expanding to accommodate growing academic and infrastructural needs.
Economic Times
an hour ago
- Economic Times
Stock Radar: M&M likely to break out from 1-year consolidation range; time to buy?
Mahindra & Mahindra Ltd (M&M), part of the automobile industry, has been consolidating in a range for almost a year now and chart patterns suggest that a breakout is likely in the near term traders can look to buy stock now or on dips for a possible target of Rs 3,650 in the next 2-4 months, suggest automobile stock hit a high of Rs 3,276 on February 10, 2025. However, the stock has remained confined in a range where Rs
